@YallRCrazy @comedyeye @OK_Dumbass @cardinalrlburke Here are a few related links. https://t.co/CZQDhQN8kX https://t.co/OZYQQfRuRg https://t.co/8FjJ0jjoaJ
RT @hildabast: This company (Vaxart) has again press released from its phase 1 results - but *still* no preprint or publication of that, 3…
This company (Vaxart) has again press released from its phase 1 results - but *still* no preprint or publication of that, 3 months later. https://t.co/SH0Ev13vU2 HT @SuleBertram So, still not much for this vax: https://t.co/p9jsu1pUkX
@Arthur12318137 @Stockdog23 @jasonptodd Ah - scratch that! I'd forgotten this https://t.co/Yk29OHaKDs & just saw they've released something else: trying to track it down now
RT @hildabast: The oral tablet Covid vaccine by Vaxart press released its phase 1 results - problematic results on neutralizing antibodies,…
RT @hildabast: The oral tablet Covid vaccine by Vaxart press released its phase 1 results - problematic results on neutralizing antibodies,…
RT @hildabast: The oral tablet Covid vaccine by Vaxart press released its phase 1 results - problematic results on neutralizing antibodies,…
The oral tablet Covid vaccine by Vaxart press released its phase 1 results - problematic results on neutralizing antibodies, though some T-cell response https://t.co/Fo74kZuXoU That's not what happened in the preclinical study: https://t.co/0UQzOjZQUd Goin
RT @NickytaLeb: $VXRT Vaxart Two oral doses of Ad5-vectored vaccine https://t.co/3LUJrJpptH
$VXRT Vaxart Two oral doses of Ad5-vectored vaccine https://t.co/3LUJrJpptH
RT @carpe_diem0820: Vaxart社が開発するCOVID-19経口ワクチンは10月に臨床試験を開始 今年上半期に3,600パーセント株価が上昇し、ヘッジファンドが株式の大半を売却し、2億ドル以上の利益を得たことに対し米国司法省が調査を開始 U.S. Inves…
RT @carpe_diem0820: Vaxart社が開発するCOVID-19経口ワクチンは10月に臨床試験を開始 今年上半期に3,600パーセント株価が上昇し、ヘッジファンドが株式の大半を売却し、2億ドル以上の利益を得たことに対し米国司法省が調査を開始 U.S. Inves…
RT @carpe_diem0820: Vaxart社が開発するCOVID-19経口ワクチンは10月に臨床試験を開始 今年上半期に3,600パーセント株価が上昇し、ヘッジファンドが株式の大半を売却し、2億ドル以上の利益を得たことに対し米国司法省が調査を開始 U.S. Inves…
RT @carpe_diem0820: Vaxart社が開発するCOVID-19経口ワクチンは10月に臨床試験を開始 今年上半期に3,600パーセント株価が上昇し、ヘッジファンドが株式の大半を売却し、2億ドル以上の利益を得たことに対し米国司法省が調査を開始 U.S. Inves…
Vaxart社が開発するCOVID-19経口ワクチンは10月に臨床試験を開始 今年上半期に3,600パーセント株価が上昇し、ヘッジファンドが株式の大半を売却し、2億ドル以上の利益を得たことに対し米国司法省が調査を開始 U.S. Investigates Vaxart’s Claims Related to Covid-19 Vaccine https://t.co/3xCKGOMOSZ https://t.co/jgjfGHYS7K
RT @annec_moore: Time well spent with Vaxart during lockdown, adenoviral mucosal #vaccine to prevent #SARS_CoV_2; now bioRxiv'ed. Thanks Va…
RT @annec_moore: Time well spent with Vaxart during lockdown, adenoviral mucosal #vaccine to prevent #SARS_CoV_2; now bioRxiv'ed. Thanks Va…
RT @carpe_diem0820: 米国のVaxartが開発するCOVID-19の経口ワクチン、マウスでの抗体産生を確認し、9/24に第1相臨床試験を登録 Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vacc…
米国のVaxartが開発するCOVID-19の経口ワクチン、マウスでの抗体産生を確認し、9/24に第1相臨床試験を登録 Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults https://t.co/6NY9XGADdd https://t.co/U9FVksiYmV
RT @hildabast: A tablet version of an Ad5 vector Covid-19 vaccine with adjuvant is recruiting for a phase 1 trial in California. The vaccin…
RT @hildabast: A tablet version of an Ad5 vector Covid-19 vaccine with adjuvant is recruiting for a phase 1 trial in California. The vaccin…
RT @hildabast: A tablet version of an Ad5 vector Covid-19 vaccine with adjuvant is recruiting for a phase 1 trial in California. The vaccin…
RT @hildabast: A tablet version of an Ad5 vector Covid-19 vaccine with adjuvant is recruiting for a phase 1 trial in California. The vaccin…
RT @hildabast: A tablet version of an Ad5 vector Covid-19 vaccine with adjuvant is recruiting for a phase 1 trial in California. The vaccin…
RT @hildabast: A tablet version of an Ad5 vector Covid-19 vaccine with adjuvant is recruiting for a phase 1 trial in California. The vaccin…
RT @hildabast: A tablet version of an Ad5 vector Covid-19 vaccine with adjuvant is recruiting for a phase 1 trial in California. The vaccin…
Which begs the question, why haven't we seen any tablet vaccines before?
A tablet version of an Ad5 vector Covid-19 vaccine with adjuvant is recruiting for a phase 1 trial in California. The vaccine is called VXA-CoV2-1. The trial: https://t.co/TogCy3bCJD Preclinical report: https://t.co/0UQzOjIg2F Background: https://t.co/tHTq
@__ice9 “Oral vaccine” in phase 1. Induces systemic and mucosal immune response. Lower risk of ADE. 🙃 https://t.co/jBISGMy32I
RT @outbreaksci: Updated #SARSCoV preprint: Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infectio…
Contribute a rapid review or request one for "Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 i..." (https://t.co/qdTH3u1XZW). "Add" or "Request" w/DOI (10.1101/2020.09.04.283853) at https://t.co/RnurTL3DyM @outbreaks
Updated #SARSCoV preprint: Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection https://t.co/qdTH3u1XZW
@realDonaldTrump @SteveFDA @SecAzar We will this fight against this terrible virus! ☝🏻☝🏻☝🏻
RT @annec_moore: Time well spent with Vaxart during lockdown, adenoviral mucosal #vaccine to prevent #SARS_CoV_2; now bioRxiv'ed. Thanks Va…
$VXRT
@__ice9 thoughts on oral adenoviral vax (Vaxart)? theoretically better: ease of use/compliance, warm transport, IgA response people are incredibly resistant to needles,add that to the general skepticism re COVID—po could add millions to vax acceptance ht
RT @annec_moore: Time well spent with Vaxart during lockdown, adenoviral mucosal #vaccine to prevent #SARS_CoV_2; now bioRxiv'ed. Thanks Va…
There we go! $VXRT @HulkCapitalPro
RT @annec_moore: Time well spent with Vaxart during lockdown, adenoviral mucosal #vaccine to prevent #SARS_CoV_2; now bioRxiv'ed. Thanks Va…
RT @annec_moore: Time well spent with Vaxart during lockdown, adenoviral mucosal #vaccine to prevent #SARS_CoV_2; now bioRxiv'ed. Thanks Va…
RT @annec_moore: Time well spent with Vaxart during lockdown, adenoviral mucosal #vaccine to prevent #SARS_CoV_2; now bioRxiv'ed. Thanks Va…
RT @annec_moore: Time well spent with Vaxart during lockdown, adenoviral mucosal #vaccine to prevent #SARS_CoV_2; now bioRxiv'ed. Thanks Va…
RT @annec_moore: Time well spent with Vaxart during lockdown, adenoviral mucosal #vaccine to prevent #SARS_CoV_2; now bioRxiv'ed. Thanks Va…
RT @annec_moore: Time well spent with Vaxart during lockdown, adenoviral mucosal #vaccine to prevent #SARS_CoV_2; now bioRxiv'ed. Thanks Va…
@POTUS The pill will re-elected you! ☝🏻☝🏻☝🏻
@jimcramer I told you ☝🏻
RT @annec_moore: Time well spent with Vaxart during lockdown, adenoviral mucosal #vaccine to prevent #SARS_CoV_2; now bioRxiv'ed. Thanks Va…
RT @annec_moore: Vaxart’s clinical vaccine candidate, containing SARS-CoV-2 spike & nucleocapsid antigens, induced neutralizing antibody (s…
RT @annec_moore: Time well spent with Vaxart during lockdown, adenoviral mucosal #vaccine to prevent #SARS_CoV_2; now bioRxiv'ed. Thanks Va…
RT @annec_moore: Time well spent with Vaxart during lockdown, adenoviral mucosal #vaccine to prevent #SARS_CoV_2; now bioRxiv'ed. Thanks Va…
RT @annec_moore: Time well spent with Vaxart during lockdown, adenoviral mucosal #vaccine to prevent #SARS_CoV_2; now bioRxiv'ed. Thanks Va…
RT @annec_moore: Time well spent with Vaxart during lockdown, adenoviral mucosal #vaccine to prevent #SARS_CoV_2; now bioRxiv'ed. Thanks Va…
Time well spent with Vaxart during lockdown, adenoviral mucosal #vaccine to prevent #SARS_CoV_2; now bioRxiv'ed. Thanks Vaxart folks & @UCCResearch @UCC @bioucc @BetterOffMalone for UCC help. Exciting clinical trials ahead for VXRT... https://t.co/wMLg
Vaxart’s clinical vaccine candidate, containing SARS-CoV-2 spike & nucleocapsid antigens, induced neutralizing antibody (systemic and mucosal) & T-cells. #COVID19 #vaccine https://t.co/17kd5Yw1gs
RT @TjbMan: They're working on an oral SARS-Cov-2 vaccine. These room temperature-stable tablets can be stored and shipped without refriger…
The paper “Pre-clinical studies of a recombinant adenoviral m...” (https://t.co/5jUJQIwb8l) has been reviewed by a set of automated tools; find the results of the analysis here: https://t.co/vHH0uLA5qy. We detected 2 of 6 rigor criteria and 19 key resource
They're working on an oral SARS-Cov-2 vaccine. These room temperature-stable tablets can be stored and shipped without refrigeration. That would be a HUGE logistics benefit
RT @princetongb: $VXRT most impressive vaccine platform to emerge from the pandemic. Triple C-19 threat: induces potent serum neutralizing…
I am glad to see this! We need an oral vaccine for public health acceptance, ease of storage & faster distribution. Great work! https://t.co/i9U21XOUG1
RT @drsusanjoh: Our research group’s paper showing Vaxart’s vaccine candidate induces both systemic and mucosal antibody responses. Check i…
RT @princetongb: $VXRT most impressive vaccine platform to emerge from the pandemic. Triple C-19 threat: induces potent serum neutralizing…
Our research group’s paper showing Vaxart’s vaccine candidate induces both systemic and mucosal antibody responses. Check it out! https://t.co/LQmYrbLCDI
Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection https://t.co/UJFV1hCjiL #immunobot
Like $VXRT and $BCRX rocket
Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection https://t.co/KAD6fARtjN
$VXRT most impressive vaccine platform to emerge from the pandemic. Triple C-19 threat: induces potent serum neutralizing antibodies to viral S protein, strong mucosal and T cell responses. Current programs also include influenza and norovirus. https://t.
RT @RNA_Biotech: Recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection https://t.co/g065Rs3iyR "spike antigen induces si…
Recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection https://t.co/g065Rs3iyR "spike antigen induces significantly higher neutralizing antibodies in the periphery and in the lungs, when the vaccine is administered mucosally. " https://t
new pre-print from $VXRT.. outstanding timing on this one w/ the MRNA downgrade. This should be good news for getting IND approved https://t.co/hEeyJ0D0nd
@NolaStocks news! Idk how relevant this is.. reading now. TOS has good summary https://t.co/1viwWDXh8H
Contribute a rapid review or request one for "Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 i..." (https://t.co/qdTH3u1XZW). "Add" or "Request" w/DOI (10.1101/2020.09.04.283853) at https://t.co/RnurTL3DyM @outbreaks
New #SARSCoV preprint: Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection https://t.co/qdTH3u1XZW
Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection https://t.co/97erOc0qOj
Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection https://t.co/9TpvFweTjU
RT @biorxivpreprint: Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection https://t.co/RX72WbO…
RT @biorxivpreprint: Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection https://t.co/RX72WbO…
RT @biorxivpreprint: Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection https://t.co/RX72WbO…
RT @biorxivpreprint: Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection https://t.co/RX72WbO…
𝗧𝗶𝘁𝗹𝗲: Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection. 𝗔𝘂𝘁𝗵𝗼𝗿𝘀: Anne C Moore, Emery G Dora, Nadine Peinovich, Kiersten P Tucker, Karen Lin, Mario Cortese, Sean Tucker https://t.co/PpFz2iYwNw https://t.co/IA
Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection https://t.co/VrJFophIdr #biorxiv_immuno
Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection https://t.co/RX72WbOsjU #bioRxiv